Biophysical properties of human antibody variable domains

Journal of Molecular Biology

Volumn 325, Issue 3, 2003, Pages 531-553

  Ewert, Stefan ^a,b   Huber, Thomas ^a   Honegger, Annemarie ^a   Plückthun, Andreas ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b ESBATech AG   (Switzerland)

Author keywords

Antibody engineering; Expression; Protein stability; scFv fragment

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; OLIGOMER;

AMINO ACID SEQUENCE; ARTICLE; BIOPHYSICS; GEL FILTRATION; HYDROPHOBICITY; MODEL; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FOLDING; PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; SOLUBILITY; THERMODYNAMICS; THERMOSTABILITY;

EID: 0037227517     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-2836(02)01237-8     Document Type: Article

References (60)

1. Hudson, P. J. (1998). Recombinant antibody fragments. Curr. Opin. Biotechnol. 9, 395-402.
2. Willuda, J., Honegger, A., Waibel, R., Schubiger, P. A., Stahel, R., Zangemeister-Wittke, U. & Plückthun, A. (1999). High thermal stability is essential for tumor targeting of antibody fragments: Engineering of a humanized anti-epithelial glycoprotein-2 (epithelial cell adhesion molecule) single-chain Fv fragment. Cancer Res. 59, 5758-5767.
3. Harris, B. (1999). Exploiting antibody-based technologies to manage environmental pollution. Trends Biotechnol. 17, 290-296.
4. Dooley, H., Grant, S. D., Harris, W. J. & Porter, A. J. (1998). Stabilization of antibody fragments in adverse environments. Biotechnol. Appl. Biochem. 28, 77-83.
5. Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M. et al. (1988). Single-chain antigen-binding proteins. Science, 242, 423-426.
6. Glockshuber, R., Malia, M., Pfitzinger, I. & Plückthun, A. (1990). A comparison of strategies to stabilize immunoglobulin Fv-fragments. Biochemistry, 29, 1362-1367.
7. Huston, J. S., Levinson, D., Mudgett-Hunter, M., Tai, M. S., Novotny, J., Margolies, M. N. et al. (1988). Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA, 85, 5879-5883.
8. Plückthun, A., Krebber, A., Horn, U., Knüpfer, U., Wenderoth, R., Nieba, L., Proba, K. & Riesenberg, D. (1996). Producing antibodies in E. coli: From PCR to fermentation. In Antibody Engineering, A Practical Approach (Mc Cafferty, J., Hoogenboom, H. R. & Chiswell, D. J., eds), pp. 203-252, Oxford University Press, New York.
9. Knappik, A. & Plückthun, A. (1995). Engineered turns of a recombinant antibody improve its in vivo folding. Protein Eng. 8, 81-89.
10. Forsberg, G., Forsgren, M., Jaki, M., Norin, M., Sterky, C., Enhorning, A. et al. (1997). Identification of framework residues in a secreted recombinant antibody fragment that control production level and localization in Escherichia coli. J. Biol. Chem. 272, 12430-12436.
11. Kipriyanov, S. M., Moldenhauer, G., Martin, A. C., Kupriyanova, O. A. & Little, M. (1997). Two amino acid mutations in an anti-human CD3 single chain Fv antibody fragment that affect the yield on bacterial secretion but not the affinity. Protein Eng. 10, 445-453.
12. Nieba, L., Honegger, A., Krebber, C. & Plückthun, A. (1997). Disrupting the hydrophobic patches at the antibody variable/constant domain interface: Improved in vivo folding and physical characterization of an engineered scFv fragment. Protein Eng. 10, 435-444.
13. Wörn, A. & Plückthun, A. (2001). Stability engineering of antibody single-chain Fv fragments. J. Mol. Biol. 305, 989-1010.
14. Wörn, A. & Plückthun, A. (1999). Different equilibrium stability behavior of ScFv fragments: Identification, classification, and improvement by protein engineering. Biochemistry, 38, 8739-8750.
15. Jäger, M. & Plückthun, A. (1999). Domain interactions in antibody Fv and scFv fragments: Effects on unfolding kinetics and equilibria. FEBS Letters, 462, 307-312.
16. Jäger, M., Gehrig, P. & Plückthun, A. (2001). The scFv fragment of the antibody hu4D5-8: Evidence for early premature domain interaction in refolding. J. Mol. Biol. 305, 1111-1129.
17. Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G. et al. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. J. Mol. Biol. 296, 57-86.
18. Hanes, J., Schaffitzel, C., Knappik, A. & Plückthun, A. (2000). Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nature Biotechnol. 18, 1287-1292.
19. Wirtz, P. & Steipe, B. (1999). Intrabody construction and expression III: Engineering hyperstable VH domains. Protein Sci. 8, 2245-2250.
20. Jäger, M. & Plückthun, A. (1999). Folding and assembly of an antibody Fv fragment, a heterodimer stabilized by antigen. J. Mol. Biol. 285, 2005-2019.
21. Ohage, E. & Steipe, B. (1999). Intrabody construction and expression. I. The critical role of VL domain stability. J. Mol. Biol. 291, 1119-1128.
22. Stevens, F. J. (2000). Four structural risk factors identify most fibril-forming kappa light chains. Amyloid, 7, 200-211.
23. Honegger, A. & Plückthun, A. (2001). Yet another numbering scheme for immunoglobulin variable domains: An automatic modeling and analysis tool. J. Mol. Biol. 309, 657-670.
24. Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L. et al. (1992). Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA, 89, 4285-4289.
25. H3 domains. Biochemistry, 41, 3628-3636.
26. Power, B. E., Ivancic, N., Harley, V. R., Webster, R. G., Kortt, A. A., Irving, R. A. & Hudson, P. J. (1992). High-level temperature-induced synthesis of an antibody VH-domain in Escherichia coli using the PelB secretion signal. Gene, 113, 95-99.
27. Myers, J. K., Pace, C. N. & Scholtz, J. M. (1995). Denaturant m values and heat capacity changes: Relation to changes in accessible surface areas of protein unfolding. Protein Sci. 4, 2138-2148.
28. Pace, C. N. & Scholtz, J. M. (1997). Measuring the conformational stability of a protein. In Protein Structure, A Practical Approach (Creighton, T. E., ed.), pp. 299-321, Oxford University Press, New York.
29. Raffen, R., Dieckman, L. J., Szpunar, M., Wunschl, C., Pokkuluri, P. R., Dave, P. et al. (1999). Physicochemical consequences of amino acid variations that contribute to fibril formation by immunoglobulin light chains. Protein Sci. 8, 509-517.
30. Honegger, A. & Plückthun, A. (2001). The influence of the buried glutamine or glutamate residue in position 6 on the structure of immunoglobulin variable domains. J. Mol. Biol. 309, 687-699.
31. Nakamura, H. (1996). Roles of electrostatic interaction in proteins. Quart. Rev. Biophys. 29, 1-90.
32. Pace, C. N. (1990). Measuring and increasing protein stability. Trends Biotechnol. 8, 93-98.
33. Koradi, R., Billeter, M. & Wüthrich, K. (1996). MOL-MOL: A program for display and analysis of macromolecular structures. J. Mol. Graph. 14, 51-55. See also pp. 29-32.
34. Eigenbrot, C., Randal, M., Presta, L., Carter, P. & Kossiakoff, A. A. (1993). X-ray structures of the antigen-binding domains from three variants of humanized anti-p185HER2 antibody 4D5 and comparison with molecular modeling. J. Mol. Biol. 229, 969-995.
35. Saul, F. A. & Poljak, R. J. (1993). Structural patterns at residue positions 9, 18, 67 and 82 in the VH framework regions of human and murine immunoglobulins. J. Mol. Biol. 230, 15-20.
36. Jung, S., Spinelli, S., Schimmele, B., Honegger, A., Pugliese, L., Cambillau, C. & Plückthun, A. (2001). The importance of framework residues H6, H7 and H10 in antibody heavy chains: Experimental evidence for a new structural subclassification of antibody VH domain. J. Mol. Biol. 309, 701-716.
37. Fink, A. L. (1998). Protein aggregation: Folding aggregates, inclusion bodies and amyloid. Fold. Des. 3, R9-23.
38. Jung, S., Honegger, A. & Plückthun, A. (1999). Selection for improved protein stability by phage display. J. Mol. Biol. 294, 163-180.
39. Ewert, S., Honegger, A. & Plückthun, A. (2002). Structural-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach. Biochemistry. In press.
40. Schiweck, W., Buxbaum, B., Schatzlein, C., Neiss, H. G. & Skerra, A. (1997). Sequence analysis and bacterial production of the anti-c-myc antibody 9E10: The VH domain has an extended CDR-H3 and exhibits unusual solubility. FEBS Letters, 414, 33-38.
41. van der Linden, R. H., Frenken, L. G., de Geus, B., Harmsen, M. M., Ruuls, R. C., Stok, W. et al. (1999). Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim. Biophys. Acta, 1431, 37-46.
42. Desmyter, A., Transue, T. R., Ghahroudi, M. A., Thi, M. H., Poortmans, F., Hamers, R. et al. (1996). Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nature Struct. Biol. 3, 803-811.
43. Decanniére, K., Desmyter, A., Lauwereys, M., Ghahroudi, M. A., Muyldermans, S. & Wyns, L. (1999). A single-domain antibody fragment in complex with RNase A: Non-canonical loop structures and nanomolar affinity using two CDR loops. Struct. Fold. Des. 7, 361-370.
44. Griffiths, A. D., Williams, S. C., Hartley, O., Tomlinson, I. M., Waterhouse, P., Crosby, W. L. et al. (1994). Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 13, 3245-3260.
45. Vaughan, T. J., Williams, A. J., Pritchard, K., Osbourn, J. K., Pope, A. R., Earnshaw, J. C. et al. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnol. 14, 309-314.
46. Tomlinson, I. M., Walter, G., Marks, J. D., Llewelyn, M. B. & Winter, G. (1992). The repertoire of human germline VH sequences reveals about fifty groups of VH segments with different hypervariable loops. J. Mol. Biol. 227, 776-798.
47. Glockshuber, R., Schmidt, T. & Plückthun, A. (1992). The disulfide bonds in antibody variable domains: Effects on stability, folding in vitro, and functional expression in Escherichia coli. Biochemistry, 31, 1270-1279.
48. Wörn, A., Auf der Maur, A., Escher, D., Honegger, A., Barberis, A. & Plückthun, A. (2000). Correlation between in vitro stability and in vivo performance of anti-GCN4 intrabodies as cytoplasmic inhibitors. J. Biol. Chem. 275, 2795-2803.
49. Visintin, M., Settanni, G., Maritan, A., Graziosi, S., Marks, J. D. & Cattaneo, A. (2002). The intracellular antibody capture technology (IACT): Towards a consensus sequence for intracellular antibodies. J. Mol. Biol. 317, 73-83.
50. Tse, E., Lobato, M. N., Forster, A., Tanaka, T., Chung, G. T. & Rabbitts, T. H. (2002). Intracellular antibody capture technology: Application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein. J. Mol. Biol. 317, 85-94.
51. Söderlind, E., Strandberg, L., Jirholt, P., Kobayashi, N., Alexeiva, V., Aberg, A. M. et al. (2000). Recombining germline-derived CDR sequences for creating diverse single-framework antibody libraries. Nature Biotechnol. 18, 852-856.
52. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P. & Neri, D. (1998). Design and use of a phage display library. Human antibodies with sub-nanomolar affinity against a marker of angiogenesis eluted from a two-dimensional gel. J. Biol. Chem. 273, 21769-21776.
53. Holt, L. J., Bussow, K., Walter, G. & Tomlinson, I. M. (2000). By-passing selection: Direct screening for antibody-antigen interactions using protein arrays. Nucl. Acids Res. 28, E72.
54. Krebber, A., Bornhauser, S., Burmester, J., Honegger, A., Willuda, J., Bosshard, H. R. & Plückthun, A. (1997). Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods, 201, 35-55.
55. Bothmann, H. & Plückthun, A. (1998). Selection for a periplasmic factor improving phage display and functional periplasmic expression. Nature Biotechnol. 16, 376-380.
56. Kabat, E. A., Wu, T. T., Perry, H. M., Gottesmann, K. S. & Foeller, C. (1991). Sequences of Proteins of Immunological Interest. NIH Publication No. 91-3242, National Technical Information Service (NTIS), Springfield, VA.
57. Bass, S., Gu, Q. & Christen, A. (1996). Multicopy suppressors of prc mutant Escherichia coli include two HtrA (DegP) protease homologs (HhoAB), DksA, and a truncated R1pA. J. Bacteriol., 178, 1154-1161.
58. Buchner, J. & Rudolph, R. (1991). Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology (N Y), 9, 157-162.
59. Lindner, P., Bauer, K., Krebber, A., Nieba, L., Kremmer, E., Krebber, C. et al. (1997). Specific detection of his-tagged proteins with recombinant anti-His tag scFv-phosphatase or scFv-phage fusions. Biotechniques, 22, 140-149.
60. Liu, N., Deillon, C., Klauser, S., Gutte, B. & Thomas, R. M. (1998). Synthesis, physicochemical characterization, and crystallization of a putative retro-coiled coil. Protein Sci. 7, 1214-1220.